A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Clinical trial NCT04394650 · COMPLETED
Trial details
- NCT number
- NCT04394650
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-18
- Primary completion
- 2024-07-03
- Enrollment
- 78
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.